Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction

Thrombosis Research

Volumn 95, Issue 1, 1999, Pages 37-47

  Takazoe, Keiji ^a   Ogawa, Hisao ^a   Yasue, Hirofumi ^a   Sakamoto, Tomohiro ^a   Oshima, Shuichi ^a   Arai, Hidekazu ^b   Moriyama, Yasushi ^a   Shimomura, Hideki ^b   Hirai, Nobutaka ^b   Kaikita, Koichi ^a   Soejima, Hirofumi ^a   Misumi, Kenji ^a   Hosoda, Kenji ^c  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b Fukuoka Tokushukai Hospital   (Japan)

^c TEIJIN LTD   (Japan)

Author keywords

Activated protein C; Myocardial infarction; Thrombin; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ALTEPLASE; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RECANALIZATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; AGED; ANTICOAGULANTS; ANTITHROMBIN III; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY VESSELS; FEMALE; HEPARIN; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C;

EID: 0033166248     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00020-1     Document Type: Article

References (36)

1. Ryan T.J., Anderson J.L., Antman E.M., Braniff B.A., Brooks N.H., Califf R.M., Hillis L.D., Hiratzka L.F., Rapaport E., Riegel B.J., Russell R.O., Smith E.E. III, Weaver W.D. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Management of Acute Myocardial Infarction) J Am Coll Cardiol. 28:1996;1328-1428.
2. Gruppo Italiano per lo Studia della Streptochinasi nell'Infarto Miocardico (GISSI) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1:1986;397-402.
3. Williams D.O., Borer J., Braunwald E., Chesebro J.H., Cohen L.S., Dalen J., Dodge H.T., Francis C.K., Knatterud G., Ludbrook P., Markis J.E., Mueller H., Desvigne-Nickens P., Passamani E.R., Powers E.R., Rao A.K., Roberts R., Ross A., Ryan T.J., Sobel B.E., Winniford M., Zaret B. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. A report from the NHLBI thrombolysis in myocardial infarction trial Circulation. 73:1986;338-346.
4. Gold H.K., Leinbach R.C., Garabedian H.D., Yasuda T., Johns J.A., Grossbard E.B., Palacios I., Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator. Prevention by a maintenance infusion Circulation. 73:1986;347-352.
5. Fenton J.W. II, Ofosu F.A., Moon D.G., Maraganore J.M. Thrombin structure and function. Why thrombin is the primary target for antithrombotics Blood Coagul Fibrinolysis. 2:1991;69-75.
6. Johnson H., Orinius E., Paul C. Fibrinopeptide A (FPA) in patients with acute myocardial infarction. Thromb Res. 16:1979;255-260.
7. Eisenberg P.R., Sherman L.A., Schectmann K., Peres J., Sobel B.E., Jaffe A.S. Fibrinopeptide A. A marker of acute coronary thrombosis Circulation. 71:1985;912-918.
8. Almér L.-O., Öhlin H. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb Res. 47:1987;335-339.
9. Gram J., Kluft C., Jespersen J. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemost. 58:1987;817-821.
10. Lucore C.L., Sobel B.E. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 77:1988;660-669.
11. Esmon C.T. Protein C. Biochemistry, physiology and clinical implications Blood. 62:1983;1155-1158.
12. Esmon C.T. The regulation of natural anticoagulant pathways. Science. 235:1987;1348-1352.
13. Ogawa H., Yasue H., Ohsima S., Ogata Y., Numata Y., Fujimoto K., Imoto N., Saito T., Hokamura Y., Takahashi T., Watanabe H., Kodama H., Morikami Y., Miyagi H., Obata K., Matsuyama K., Sakaino N., Nakamura T., Wakita T. Effect of the initial bolus volume of recombinant tissue-type plasminogen activator on coronary recanalization and infarct size in Japanese acute myocardial infarction patients. Jpn Circ J. 59:1995;663-672.
14. The TIMI Study Group The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings N Engl J Med. 312:1985;932-936.
15. Gruber A., Griffin J.H. Direct detection of activated protein C in blood from human subjects. Blood. 79:1992;2340-2348.
16. Wakabayashi K., Sakata Y., Aoki N. Conformation-specific monoclonal antibodies to the calcium-induced structure of protein C. J Biol Chem. 261:1986;11097-11105.
17. Ohno Y., Kato H., Morita T., Iwanaga S., Takada K., Sakakibara S., Stenflo J. A new fluologenic peptide substrate for vitamin K-dependent blood coagulation factor, bovine protein C. J Biochem. 90:1981;1387-1395.
18. Pelzer H., Schwarz A., Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 59:1988;101-106.
19. Eriksson E., Rånby M., Gyzander E., Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res. 50:1988;91-101.
20. Fuster V., Lewis A. Conner Memorial Lecture. Mechanism leading to myocardial infarction. Insights from studies of vascular biology Circulation. 90:1994;2126-2146.
21. Sakamoto T., Yasue H., Ogawa H., Misumi I., Masuda T. Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol. 70:1992;271-276.
22. Marlar R.A., Kleiss A.J., Griffin J.H. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 59:1982;1067-1072.
23. Fernández J.A., Petäjä J., Gruber A., Griffin J.H. Activated protein C correlates inversely with thrombin levels in resting healthy individuals. Am J Hematol. 56:1997;29-31.
24. Sakamoto T., Ogawa H., Yasue H., Oda Y., Kitajima S., Tsumoto K., Mizokami H. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary thrombosis Circulation. 90:1994;427-432.
25. Taylor F.B. Jr., Chang A., Esmon C.T., D'Angelo A., Vigano-D'Angelo S., Blick K.E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 79:1987;918-925.
26. Gruber A., Hanson S.R., Kelly A.B., Yan B.S., Bang N., Griffin J.H., Harker L.A. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation. 82:1990;578-585.
27. Araki H., Nishi K., Ishihara N., Okajima K. Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries. Thromb Res. 62:1991;209-216.
28. Okajima K., Imamura H., Koga S., Inoue M., Takatsuki K., Aoki N. Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol. 33:1990;277-278.
29. Gruber A., Pai A., Kiss R.G., Sas G., Griffin J.H. Generation of activated protein C during thrombolysis. Lancet. 342:1993;1275-1276.
30. Gulba D.C., Barthels M., Westhoff-Bleck M., Jost S., Rafflenbeul W., Daniel W.G., Hecker H., Lichtlen P.R. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation. 83:1991;937-944.
31. Hanson S.R., Griffin J.H., Harker L.A., Kelly A.B., Esmon C.T., Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest. 92:1993;2003-2012.
32. Hirashima O., Ogawa H., Oshima S., Sakamoto T., Honda Y., Sakata S., Masuda T., Miyao Y., Yasue H. Serial change of plasminogen activator inhibitor activity in acute myocardial infarction. Difference between thrombolytic therapy and direct coronary angioplasty Am Heart J. 130:1995;933-939.
33. Fujii S., Sobel B.E. Induction of plasminogen activator inhibitor by products released from platelets. Circulation. 82:1990;1485-1493.
34. Sakata Y., Curriden S., Lawrence D., Griffin J.H., Loskutoff D.J. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases activator activity. Proc Natl Acad Sci USA. 82:1985;1121-1125.
35. Van Hinsbergh V.W.M., Bertina R.M., Van Wijngaarden A., Tiburg N.H., Emeiss J.J., Haverhake F. Activated protein C decreases plasminogen activator inhibitor activity in endothelial cell-conditioned medium. Blood. 65:1985;441-451.
36. Sakata Y., Loskutoff D.J., Gladson C.L., Hekman C.M., Griffin J.H. Mechanism of protein C-dependent clot lysis. Role of plasminogen activator inhibitor Blood. 68:1986;1218-1223.